临床试验/EUCTR2007-003348-31-SE

EUCTR2007-003348-31-SE

进行中（未招募）

不适用

Progesterone at imminent premature birthProgesteron vid hotande förtidsbörd

Department of Woman and Child health, Karolinska University Hospital0 个研究点2007年12月17日

适应症In this randomised, placebo-controlled pilot study the treatment group (n=30) will recieve a daily application of vaginal gel containing progesterone 90 mg/dose (Crinone, Seronomerck) until rupture of fetal membranes, partus or 34 gestational weeks. The control group (n=30) will recieve a daily application of vaginal gel (Replens, Campus Pharma), which is identical to Crinone except for progesterone hormone, until rupture of fetal membranes, partus or 34 gestational weeks.

概览

阶段: 不适用
干预措施: 未指定
疾病 / 适应症: In this randomised, placebo-controlled pilot study the treatment group (n=30) will recieve a daily application of vaginal gel containing progesterone 90 mg/dose (Crinone, Seronomerck) until rupture of fetal membranes, partus or 34 gestational weeks. The control group (n=30) will recieve a daily application of vaginal gel (Replens, Campus Pharma), which is identical to Crinone except for progesterone hormone, until rupture of fetal membranes, partus or 34 gestational weeks.
发起方: Department of Woman and Child health, Karolinska University Hospital
状态: 进行中（未招募）
最后更新: 14年前

概览研究者入排标准结局指标相似试验

概览

简要总结

暂无简介。

注册库

who.int

开始日期

2007年12月17日

结束日期

待定

最后更新

14年前

研究类型

Interventional clinical trial of medicinal product

性别

Female

研究者

发起方

Department of Woman and Child health, Karolinska University Hospital

入排标准

入选标准

•Pregnant women with imminent premature birth 24\+0 to 34\+0 gestational weeks.
•Are the trial subjects under 18? yes
•Number of subjects for this age range:
•F.1\.2 Adults (18\-64 years) yes
•F.1\.2\.1 Number of subjects for this age range
•F.1\.3 Elderly (\>\=65 years) no
•F.1\.3\.1 Number of subjects for this age range

排除标准

•Maternal systemic disease, pregnancy complication, non\-simplex pregnancy, previous uterine or cervical surgery, placenta previa, planned cervical cerclage.

结局指标

主要结局

未指定

相似试验

进行中（未招募）

1 期

PEPPER-trialPlacenta previa, preterm birthTherapeutic area: Diseases [C] - Female Urogenital Diseases and Pregnancy Complications [C13]

CTIS2023-507763-18-01Amsterdam UMC142

招募中

不适用

Pessary (cervical Ring) plus Progesterone to prevent Preterm delivery

RBR-3t8przIVERSIDADE ESTADUAL DE CAMPINAS

已完成

3 期

Pessary or Progesterone to Prevent Preterm delivery in women with short cervical length.preterm birth10028920

NL-OMON50366Academisch Medisch Centrum960

进行中（未招募）

1 期

Pessary or Progesterone to Prevent Preterm delivery in women with short cervical lengthpreterm birthMedDRA version: 20.1Level: LLTClassification code 10023555Term: Labour prematureSystem Organ Class: 10036585 - Pregnancy, puerperium and perinatal conditionsMedDRA version: 20.1Level: LLTClassification code 10023545Term: Labor prematureSystem Organ Class: 10036585 - Pregnancy, puerperium and perinatal conditionsMedDRA version: 20.0Level: LLTClassification code 10036594Term: Premature birthSystem Organ Class: 10036585 - Pregnancy, puerperium and perinatal conditionsMedDRA version: 20.1Level: PTClassification code 10036600Term: Premature labourSystem Organ Class: 10036585 - Pregnancy, puerperium and perinatal conditionsMedDRA version: 20.1Level: LLTClassification code 10036599Term: Premature laborSystem Organ Class: 10036585 - Pregnancy, puerperium and perinatal conditionsTherapeutic area: Analytical, Diagnostic and Therapeutic Techniques and Equipment [E] - Therapeutic techniques [E02]

EUCTR2013-002884-24-NLAMC960

招募中

不适用

Quadruple-P follow-up<p>Women with short cervical length during mid-trimester, therefore having a highrer risk on preterm birth</p>

NL-OMON26646one600